Orchestra BioMed CEO to Present at Wells Fargo Healthcare Conference
Event summary
- Orchestra BioMed CEO David Hochman to present at Wells Fargo Healthcare Conference on September 10, 2026.
- One-on-one investor meetings scheduled for September 9 and 10, 2026.
- Company's two flagship products, AVIM Therapy and Virtue SAB, in pivotal clinical trials.
- AVIM Therapy has FDA Breakthrough Device Designation for uncontrolled hypertension.
- Virtue SAB has FDA Breakthrough Device Designation for coronary in-stent restenosis and peripheral artery disease.
The big picture
Orchestra BioMed's participation in the Wells Fargo Healthcare Conference underscores its focus on accelerating high-impact biomedical technologies through strategic collaborations. The company's flagship products target multi-billion-dollar markets, with AVIM Therapy addressing uncontrolled hypertension and Virtue SAB targeting atherosclerotic artery disease. The strategic partnership with Medtronic positions Orchestra BioMed to capitalize on the global leader in cardiac pacing therapies, potentially enhancing its market reach and product development capabilities.
What we're watching
- Clinical Progress
- The pace at which AVIM Therapy and Virtue SAB advance through pivotal clinical trials will determine their market potential.
- Regulatory Dynamics
- Whether Orchestra BioMed can leverage its FDA Breakthrough Device Designations to accelerate approvals and commercialization.
- Strategic Partnerships
- How the collaboration with Medtronic will impact the development and commercialization of AVIM Therapy.